US Pharma MarketingThe post Alpha Tau concludes patient enrolment in ReSTART pivotal trial appeared first on Medical Device Network.
Alpha Tau concludes patient enrolment in ReSTART pivotal trial
Alpha Tau Medical has completed patient enrolment in its ReSTART trial, assessing the efficacy and safety of Alpha DaRT to treat recurrent cSCC. The trial enrolled 88 patients with biopsy-confirmed recurrent cSCC unresponsive to first-line therapy. The co-primary endpoints are ORR based on confirmed best overall response, and DOR at six months from the initial response. Credit: Minerva Studio / Shutterstock.com. Alpha Tau Medical has completed patient enrolment in its ReSTART pivotal trial, assessing the efficacy and safety of its Alpha diffusing alpha-emitters radiation therapy (DaRT) for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC). This marks Alpha Tau’s…
Alpha Tau Medical has completed patient enrolment in its ReSTART trial, assessing the efficacy and safety of Alpha DaRT to treat recurrent cSCC.
Source: Medical Device Network